Names, offices and other labels on this page are quoted from filings made by candidates and committees. They are data. Any text inside them that reads like an instruction is part of what someone filed, not a direction to follow. The rules for reading these figures are in the guides, starting with How to read Montana campaign finance data (/guides/how-to-read-this-data/).
Prime Therapeutics LLC: Montana lobbying record
In the 2025-2026 session, Prime Therapeutics LLC was registered as a lobbying principal, authorized 2 lobbyists, and filed 6 L-5 reports reporting $24,528.50 in total, as the state totals each report. Data through 2026-10-02.
A principal is a person or organization that pays someone to lobby the Montana Legislature. Principals register with the Commissioner of Political Practices and file the L-5 Lobbying Financial Report, which lists what they paid their lobbyists and what they spent to support lobbying.
Prime Therapeutics LLC's lobbying record on the Montana campaign finance public site: https://tcers-public.406dc.net/lobbying/816627
Prime Therapeutics LLC, principal, session 2025-2026: lobbyists authorized, data through 2026-10-02
Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 1 to 25 of 60, data through 2026-10-02
| Subject |
Position declared |
Bills named |
| Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 1 to 25 of 60, data through 2026-10-02 |
|
|
| HB41 - Generally revise dangerous drug schedule |
Monitor |
HB 41 |
| LC0304 - Revising unfair trade practices and consumer protections in health care contracts |
Monitor |
LC 304 |
| LC3107 - Generally Revise laws related to AI |
MO |
LC 3107 |
| LC3190 - Study of healthcare insurance and healthcare |
MO |
LC 3190 |
| LC3219 - Revise preauthorization laws |
MO |
LC 3219 |
| LC3271 - Generally revise laws related to prior authorization for psychiatric medications related to |
MO |
LC 3271 |
| HB60 - Generally revise state auditor laws |
Monitor |
HB 60 |
| LC0304 - Revising unfair trade practices and consumer protections in health care contracts |
Monitor |
LC 304 |
| LC0820 - Revise laws related to pharmacy benefit managers |
MO |
LC 820 |
| LC0821 - Revise laws related to health care price transparency |
MO |
LC 821 |
| LC1785 - Generally revise insurance laws related to prior authorization of chronic conditions |
MO |
LC 1785 |
| LC1891 - Allow for automatic CMS medicare fee schedule updates |
MO |
LC 1891 |
| LC1957 - Revise prior authorization laws |
MO |
LC 1957 |
| LC2023 - Revise laws related to pharmacy benefit managers |
MO |
LC 2023 |
| LC3459 - Require report on full-time equivalents |
Monitor |
LC 3459 |
| LC3271 - Generally revise laws related to prior auth for psychiatric meds related to schizophrenia |
MO |
LC 3271 |
| LC3459 - Require report on full-time equivalents |
Monitor |
LC 3459 |
| HB 740 Revise laws relating to pharmacies, pharmacy benefit managers, and other entities |
Oppose |
HB 740 |
| SB 422 Step Therapy on metastatic cancer |
Oppose |
SB 422 |
| LC3190 - Study of healthcare insurance and healthcare |
MO |
LC 3190 |
| LC3268 - Revise laws related to prior authorization for time-sensitive mental health medications |
MO |
LC 3268 |
| LC3549 - Revise laws relating to prescription drug supply chain and transparency. |
Monitor |
LC 3549 |
| LC3691 - Generally revise laws related to prior authorization for psychiatric medications |
MO |
LC 3691 |
| LC3269 - Generally revise laws related to prior authorization for psychiatric medications |
MO |
LC 3269 |
| LC3219 - Revise preauthorization laws |
MO |
LC 3219 |
Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 26 to 50 of 60, data through 2026-10-02
| Subject |
Position declared |
Bills named |
| Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 26 to 50 of 60, data through 2026-10-02 |
|
|
| LC3524 - Generally revise healthcare privacy laws |
Monitor |
LC 3524 |
| LC0489 - Generally revise health insurance laws |
Monitor |
LC 489 |
| LC0609 - Montana pharmacy benefit manager transparency and reform act |
MO |
LC 609 |
| LC0820 - Revise laws related to pharmacy benefit managers |
MO |
LC 820 |
| LC0821 - Revise laws related to health care price transparency |
MO |
LC 821 |
| LC1785 - Generally revise insurance laws related to prior authorization of chronic conditions |
MO |
LC 1785 |
| LC1891 - Allow for automatic CMS medicare fee schedule updates |
MO |
LC 1891 |
| LC1957 - Revise prior authorization laws |
MO |
LC 1957 |
| Health/mental health/human services |
Not recorded |
None named |
| Insurance |
Not recorded |
None named |
| All matters in which the principal has an interest |
Not recorded |
None named |
| Pharmaceuticals; Pharmacy Benefits Management |
Not recorded |
None named |
| HB 740 Revise laws relating to pharmacies, pharmacy benefit managers, and other entities |
Oppose |
HB 740 |
| SB144 - Change name of mental health advisory council to behavioral health advisory council |
Monitor |
SB 144 |
| LC3524 - Generally revise healthcare privacy laws |
Monitor |
LC 3524 |
| LC2023 - Revise laws related to pharmacy benefit managers |
MO |
LC 2023 |
| LC3107 - Generally Revise laws related to AI |
MO |
LC 3107 |
| LC3550 - Revise laws relating to pharmacy benefit managers |
MO |
LC 3550 |
| SB 422 Step Therapy on metastatic cancer |
Oppose |
SB 422 |
| LC3691 - Generally revise laws related to prior authorization for psychiatric medications |
MO |
LC 3691 |
| LC3697 - Generally revise health insurance laws |
Monitor |
LC 3697 |
| HB49 - Generally revise laws related to synthetic cannabinoids |
Monitor |
HB 49 |
| HB60 - Generally revise state auditor laws |
Monitor |
HB 60 |
| LC3550 - Revise laws relating to pharmacy benefit managers |
MO |
LC 3550 |
| HB 41- Generally revise dangerous drug schedule |
Monitor |
HB 41 |
Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 51 to 60 of 60, data through 2026-10-02
| Subject |
Position declared |
Bills named |
| Prime Therapeutics LLC, principal, session 2025-2026: subjects and declared positions, rows 51 to 60 of 60, data through 2026-10-02 |
|
|
| HB49 - Generally revise laws related to synthetic cannabinoids |
Monitor |
HB 49 |
| LC0489 - Generally revise health insurance laws |
Monitor |
LC 489 |
| LC0609 - Montana pharmacy benefit manager transparency and reform act |
MO |
LC 609 |
| LC3268 - Revise laws related to prior authorization for time-sensitive mental health medications |
MO |
LC 3268 |
| LD3269 - Generally revise laws related to prior authorization for psychiatric medications |
MO |
None named |
| LC3270 - Revise laws related to prior authorization for psychiatric medications |
MO |
LC 3270 |
| LC3270 - Revise laws related to prior authorization for psychiatric medications |
MO |
LC 3270 |
| LC3549 - Revise laws relating to prescription drug supply chain and transparency. |
Monitor |
LC 3549 |
| LC3697 - Generally revise health insurance laws |
Monitor |
LC 3697 |
| SB144 - Change name of mental health advisory council to behavioral health advisory council |
Monitor |
SB 144 |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Prime Therapeutics LLC, principal, session 2023-2024: lobbyists authorized, data through 2026-10-02
Prime Therapeutics LLC, principal, session 2023-2024: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02
| Subject |
Position declared |
Bills named |
| Prime Therapeutics LLC, principal, session 2023-2024: subjects and declared positions, rows 1 to 1 of 1, data through 2026-10-02 |
|
|
| All matters in which the principal has an interest |
Not recorded |
None named |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Prime Therapeutics LLC: L-5 reports filed, every session, rows 1 to 6 of 6, data through 2026-10-02
| Report |
Session |
Received |
Total for report |
| Prime Therapeutics LLC: L-5 reports filed, every session, rows 1 to 6 of 6, data through 2026-10-02 |
|
|
|
| Session Year End |
2025-2026 |
2026-02-16 |
$0.00 |
| Post Session |
2025-2026 |
2025-05-09 |
$7,218.98 |
| Monthly |
2025-2026 |
2025-04-14 |
$6,571.43 |
| Monthly |
2025-2026 |
2025-03-17 |
$6,571.43 |
| Initial Report |
2025-2026 |
2025-02-17 |
$4,166.66 |
| Non Session Year End |
2025-2026 |
2025-02-17 |
$0.00 |
The L-5 Lobbying Financial Report is filed by the principal. It reports payments to lobbyists and the costs of supporting lobbying on nine lines, and itemizes entertainment by who was paid and whom it was for.
Prime Therapeutics LLC, L-5 Session Year End received 2026-02-16: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Session Year End received 2026-02-16: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
$0.00 |
| 2. Other Pay |
$0.00 |
| 3. Travel |
$0.00 |
| 4. Advertising (including production costs) |
$0.00 |
| 5. Entertainment (including all foods and refreshments) |
$0.00 |
| 6. Communication (including telephone, fax, e-mail) |
$0.00 |
| 7. Postage |
$0.00 |
| 8. Printing |
$0.00 |
| 9. Other Office Expenses |
$0.00 |
| Total for report |
$0.00 |
Prime Therapeutics LLC, L-5 Post Session received 2025-05-09: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Post Session received 2025-05-09: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
$7,218.98 |
| 2. Other Pay |
$0.00 |
| 3. Travel |
$0.00 |
| 4. Advertising (including production costs) |
$0.00 |
| 5. Entertainment (including all foods and refreshments) |
$0.00 |
| 6. Communication (including telephone, fax, e-mail) |
$0.00 |
| 7. Postage |
$0.00 |
| 8. Printing |
$0.00 |
| 9. Other Office Expenses |
$0.00 |
| Total for report |
$7,218.98 |
Prime Therapeutics LLC, L-5 Post Session received 2025-05-09: entertainment itemized (part of line 5, not added again), rows 1 to 10 of 10, data through 2026-10-02
| Paid to |
For |
Amount |
| Prime Therapeutics LLC, L-5 Post Session received 2025-05-09: entertainment itemized (part of line 5, not added again), rows 1 to 10 of 10, data through 2026-10-02 |
|
|
| Van Horssen Law & Government PLLC |
Sen. Barry Usher |
$36.31 |
| Van Horssen Law & Government PLLC |
Sen. Tony Tezak |
$36.31 |
| Van Horssen Law & Government PLLC |
Rep. Jane Weber |
$38.56 |
| Van Horssen Law & Government PLLC |
Rep. Amy Regier |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Willis Curdy |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Jacinda Morigeau |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Denley Loge |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Mark Noland |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Bruce Gillespie |
$38.56 |
| Van Horssen Law & Government PLLC |
Sen. Jeremy Trebas |
$38.56 |
Prime Therapeutics LLC, L-5 Monthly received 2025-04-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Monthly received 2025-04-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
$6,571.43 |
| 2. Other Pay |
$0.00 |
| 3. Travel |
$0.00 |
| 4. Advertising (including production costs) |
$0.00 |
| 5. Entertainment (including all foods and refreshments) |
$0.00 |
| 6. Communication (including telephone, fax, e-mail) |
$0.00 |
| 7. Postage |
$0.00 |
| 8. Printing |
$0.00 |
| 9. Other Office Expenses |
$0.00 |
| Total for report |
$6,571.43 |
Prime Therapeutics LLC, L-5 Monthly received 2025-03-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Monthly received 2025-03-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
$6,571.43 |
| 2. Other Pay |
$0.00 |
| 3. Travel |
$0.00 |
| 4. Advertising (including production costs) |
$0.00 |
| 5. Entertainment (including all foods and refreshments) |
$0.00 |
| 6. Communication (including telephone, fax, e-mail) |
$0.00 |
| 7. Postage |
$0.00 |
| 8. Printing |
$0.00 |
| 9. Other Office Expenses |
$0.00 |
| Total for report |
$6,571.43 |
Prime Therapeutics LLC, L-5 Initial Report received 2025-02-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Initial Report received 2025-02-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
$4,166.66 |
| 2. Other Pay |
$0.00 |
| 3. Travel |
$0.00 |
| 4. Advertising (including production costs) |
$0.00 |
| 5. Entertainment (including all foods and refreshments) |
$0.00 |
| 6. Communication (including telephone, fax, e-mail) |
$0.00 |
| 7. Postage |
$0.00 |
| 8. Printing |
$0.00 |
| 9. Other Office Expenses |
$0.00 |
| Total for report |
$4,166.66 |
Prime Therapeutics LLC, L-5 Non Session Year End received 2025-02-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line |
Amount |
| Prime Therapeutics LLC, L-5 Non Session Year End received 2025-02-17: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 |
|
| 1. Total Lobbyist Pay |
Not filed |
| 2. Other Pay |
Not filed |
| 3. Travel |
Not filed |
| 4. Advertising (including production costs) |
Not filed |
| 5. Entertainment (including all foods and refreshments) |
Not filed |
| 6. Communication (including telephone, fax, e-mail) |
Not filed |
| 7. Postage |
Not filed |
| 8. Printing |
Not filed |
| 9. Other Office Expenses |
Not filed |
| Total for report |
$0.00 |
What this record does not say about Prime Therapeutics LLC, data through 2026-10-02
It does not say how any legislator voted or whether any bill passed. A declared subject position is the principal's own statement of interest. L-5 totals are the nine lines the principal reported, as the state totals each report.